Neurogene Inc NGNE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/15/24 EDT
33.59UNCH (UNCH)
Volume
50,030
52 week range
12.20 - 53.00
Loading...
  • Open32.16
  • Day High34.00
  • Day Low32.16
  • Prev Close31.55
  • 52 Week High53.00
  • 52 Week High Date03/22/24
  • 52 Week Low12.20
  • 52 Week Low Date08/14/23

Key Stats

  • Market Cap432.158M
  • Shares Out12.87M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta1.36
  • YTD % Change73.32

KEY STATS

  • Open32.16
  • Day High34.00
  • Day Low32.16
  • Prev Close31.55
  • 52 Week High53.00
  • 52 Week High Date03/22/24
  • 52 Week Low12.20
  • 52 Week Low Date08/14/23
  • Market Cap432.158M
  • Shares Out12.87M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta1.36
  • YTD % Change73.32

RATIOS/PROFITABILITY

  • EPS (TTM)-4.58
  • P/E (TTM)-7.33
  • Fwd P/E (NTM)-7.81
  • EBITDA (TTM)-55.282M
  • ROE (TTM)-30.96%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-76.68%
  • Debt To Equity (MRQ)0.06%

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Neurogene Inc

 

Profile

MORE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease...
Rachel McMinn Ph.D.
Chairman of the Board, Chief Executive Officer
Christine Mikail J.D.
President, Chief Financial Officer
Address
535 W 24Th Street, 5Th Floor
New York, NY
10011
United States